The drug registration certificate for the two-pyridoxine drug fumarate novove diamide tablets was obtained.

Fumaric acid novove dipyridide tablets were accepted by the National Drug Review Center on January 17, 2019.
This product is a medical insurance class B products, with more powerful antiviral efficacy, zero resistance and pregnancy B and other advantages, by the national guidelines for the prevention and treatment of chronic hepatitis B is unanimously recommended as the treatment of chronic hepatitis B first-line drugs, suitable for the treatment of adults and children 12 years of age and older chronic hepatitis B infection and human immunodeficiency virus type 1 (HIV-1) infection.
fumarate nofove diamide tablets were originally developed by Gilead in the United States.
domestic production enterprises have Zhengda Tianqing, Guangshengtang, Chengdu Beite, Qilu Pharmaceuticals and Anhui Baker and other manufacturers.
0.15g and 0.20g of the specifications also declared by the Company in January 2019 and are currently being reviewed and approved.
.